Why You Should (and Shouldn’t) Buy GW Pharmaceuticals Plc


Image Source: Getty Images.

Unlike most biopharma stocks, GW Pharmaceuticals (NASDAQ:GWPH), a British company developing marijuana-based medicines, has turned in a stellar 2016. Specifically, the company’s shares are now up by nearly 20% year to date and have simply crushed the performance of the iShares Nasdaq Biotechnology ETF:

IBB data by YCharts.

GW’s unusual strength during this turbulent period for biopharma stems from its top clinical asset, Epidiolex, hitting the mark in two late-stage studies for the rare forms of childhood epilepsy known as Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

Given the stock’s ability to swim against the stream, so to speak, we asked two of our regular healthcare contributors if investors should continue to buy this top performer, or simply watch GW from the safety of the sidelines. Here’s what they had to say.  

Epidiolex and bureaucracy say buy